{"id":"acetazolamide","rwe":[{"pmid":"41898586","year":"2026","title":"p-Aminobenzene-Sulfonamide Derivatives of Substituted Pyrimidines as Human Carbonic Anhydrase Inhibitors.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41896728","year":"2026","title":"Epidemiology, pharmacological treatment and invasive management of idiopathic intracranial hypertension in Austria: a nationwide, hospital-based, controlled analysis of insurance data.","finding":"","journal":"The journal of headache and pain","studyType":"Clinical Study"},{"pmid":"41890785","year":"2026","title":"Using selective laser trabeculoplasty to manage glaucoma in a child with phakomatosis pigmentovascularis.","finding":"","journal":"American journal of ophthalmology case reports","studyType":"Clinical Study"},{"pmid":"41890698","year":"2026","title":"Efficacy and Safety of Carbonic Anhydrase Inhibitors in the Management of Central Serous Chorioretinopathy.","finding":"","journal":"Journal of vitreoretinal diseases","studyType":"Clinical Study"},{"pmid":"41884526","year":"2026","title":"Isotretinoin-induced Intracranial Hypertension Presenting as Unilateral Pulsatile Tinnitus.","finding":"","journal":"Otology & neurotology open","studyType":"Clinical Study"}],"_fda":{"id":"a68d90ee-c8ca-4f10-94a5-6259c4922d48","set_id":"0700a910-79aa-4431-aecf-637fe14fcae8","openfda":{"nui":["N0000175517","N0000000235","M0020790"],"upc":["0323155288018","0323155288100","0323155287011","0323155287103"],"unii":["O3FX965V0I"],"route":["ORAL"],"rxcui":["197303","197304"],"spl_id":["a68d90ee-c8ca-4f10-94a5-6259c4922d48"],"brand_name":["acetazolamide"],"spl_set_id":["0700a910-79aa-4431-aecf-637fe14fcae8"],"package_ndc":["23155-287-10","23155-287-01","23155-288-01","23155-288-10"],"product_ndc":["23155-287","23155-288"],"generic_name":["ACETAZOLAMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Sulfonamides [CS]"],"substance_name":["ACETAZOLAMIDE"],"pharm_class_epc":["Carbonic Anhydrase Inhibitor [EPC]"],"pharm_class_moa":["Carbonic Anhydrase Inhibitors [MoA]"],"manufacturer_name":["Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc."],"application_number":["ANDA205530"],"is_original_packager":[true]},"version":"10","warnings":["WARNINGS Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias, and anaphylaxis. Sensitizations may recur when a sulfonamide is readministered irrespective of the route of administration. If signs of hypersensitivity or other serious reactions occur, discontinue use of this drug. Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported."],"pregnancy":["Pregnancy: Teratogenic effects Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE No specific antidote is known. Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an acidotic state, and central nervous effects might be expected to occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Supportive measures are required to restore electrolyte and pH balance. The acidotic state can usually be corrected by the administration of bicarbonate. Despite its high intraerythrocytic distribution and plasma protein binding properties, acetazolamide is dialyzable. This may be particularly important in the management of acetazolamide overdosage when complicated by the presence of renal failure."],"description":["DESCRIPTION Acetazolamide, an inhibitor of the enzyme carbonic anhydrase is a white to faintly yellowish white crystalline, odorless powder, weakly acidic, very slightly soluble in water and slightly soluble in alcohol. The chemical name for acetazolamide is N -(5-Sulfamoyl-1,3,4-thiadiazol-2-yl) acetamide and has the following chemical structure: Molecular Weight: 222.24 Molecular Formula: C 4 H 6 N 4 O 3 S 2 Acetazolamide tablets, USP are available for oral administration each containing 125 mg and 250 mg of acetazolamide respectively. Additionally, they contain the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, sodium lauryl sulfate, and sodium starch glycolate. structure"],"precautions":["PRECAUTIONS General Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paresthesia. Increasing the dose often results in a decrease in diuresis. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure diuresis in complete refractory failure. Choroidal effusion and choroidal detachment have been reported after the use of acetazolamide in the post-operative period following ophthalmic surgery. Discontinue acetazolamide tablets if choroidal effusion and/or choroidal detachment is suspected. Information for Patients Adverse reactions common to all sulfonamide derivatives may occur: anaphylaxis, fever, rash (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), crystalluria, renal calculus, bone marrow depression, thrombocytopenic purpura, hemolytic anemia, leukopenia, pancytopenia, and agranulocytosis. Caution is advised for early detection of such reactions and the drug should be discontinued and appropriate therapy instituted. In patients with pulmonary obstruction or emphysema where alveolar ventilation may be impaired, acetazolamide, which may precipitate or aggravate acidosis, should be used with caution. Gradual ascent is desirable to try to avoid acute mountain sickness. If rapid ascent is undertaken and acetazolamide tablets are used, it should be noted that such use does not obviate the need for prompt descent if severe forms of high altitude sickness occur, ie, high altitude pulmonary edema (HAPE) or high altitude cerebral edema. Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported (see WARNINGS ). Both increases and decreases in blood glucose levels have been described in patients treated with acetazolamide. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus. Acetazolamide treatment may cause electrolyte imbalances, including hyponatremia and hypokalemia, as well as metabolic acidosis. Therefore, periodic monitoring of serum electrolytes is recommended. Particular caution is recommended in patients with conditions that are associated with, or predispose a patient to, electrolyte and acid/base imbalances, such as patients with impaired renal function (including elderly patients; see PRECAUTIONS, Geriatric Use ), patients with diabetes mellitus, and patients with impaired alveolar ventilation. Some adverse reactions to acetazolamide, such as drowsiness, fatigue, and myopia, may impair the ability to drive and operate machinery. Laboratory Tests To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating acetazolamide tablet therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is recommended. Drug Interactions Aspirin - See WARNINGS . Acetazolamide modifies phenytoin metabolism with increased serum levels of phenytoin. This may increase or enhance the occurrence of osteomalacia in some patients receiving chronic phenytoin therapy. Caution is advised in patients receiving chronic concomitant therapy. By decreasing the gastrointestinal absorption of primidone, acetazolamide may decrease serum concentrations of primidone and its metabolites, with a consequent possible decrease in anticonvulsant effect. Caution is advised when beginning, discontinuing, or changing the dose of acetazolamide in patients receiving primidone. Because of possible additive effects with other carbonic anhydrase inhibitors, concomitant use is not advisable. Acetazolamide may increase the effects of other folic acid antagonists. Acetazolamide may increase or decrease blood glucose levels. Consideration should be taken in patients being treated with antidiabetic agents. Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. Acetazolamide reduces urinary excretion of quinidine and may enhance its effect. Acetazolamide may prevent the urinary antiseptic effect of methenamine. Acetazolamide increases lithium excretion and the lithium may be decreased. Acetazolamide and sodium bicarbonate used concurrently increases the risk of renal calculus formation. Acetazolamide may elevate cyclosporine levels. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of acetazolamide have not been conducted. In a bacterial mutagenicity assay, acetazolamide was not mutagenic when evaluated with and without metabolic activation. The drug had no effect on fertility when administered in the diet to male and female rats at a daily intake of up to 4 times the recommended human dose of 1,000 mg in a 50 kg individual. Pregnancy: Teratogenic effects Acetazolamide, administered orally or parenterally, has been shown to be teratogenic (defects of the limbs) in mice, rats, hamsters, and rabbits. There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from acetazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. Acetazolamide should only be used by nursing women if the potential benefit justifies the potential risk to the child. Pediatric Use The safety and effectiveness of acetazolamide in pediatric patients have not been established. Growth retardation has been reported in children receiving long-term therapy, believed secondary to chronic acidosis. Geriatric Use Metabolic acidosis, which can be severe, may occur in the elderly with reduced renal function. Clinical studies of acetazolamide did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Acetazolamide Tablets USP, 125 mg are available for oral administration as white to off white, round tablet, debossed HP 287 on one side and scored on other side. They are supplied as follows: Bottles of 100 Tablets NDC 23155-287-01 Bottles of 1,000 Tablets NDC 23155-287-10 Acetazolamide Tablets USP, 250 mg are available for oral administration as white to off white, round tablet, debossed HP 288 on one side and scored in quarters on other side. They are supplied as follows: Bottles of 100 Tablets NDC 23155-288-01 Bottles of 1,000 Tablets NDC 23155-288-10 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep container tightly closed. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000129US07 Revised: 02/2026 logo"],"pediatric_use":["Pediatric Use The safety and effectiveness of acetazolamide in pediatric patients have not been established. Growth retardation has been reported in children receiving long-term therapy, believed secondary to chronic acidosis."],"effective_time":"20260225","nursing_mothers":["Nursing Mothers Because of the potential for serious adverse reactions in nursing infants from acetazolamide, a decision should be made whether to discontinue nursing or to discontinue the drug taking into account the importance of the drug to the mother. Acetazolamide should only be used by nursing women if the potential benefit justifies the potential risk to the child."],"laboratory_tests":["Laboratory Tests To monitor for hematologic reactions common to all sulfonamides, it is recommended that a baseline CBC and platelet count be obtained on patients prior to initiating acetazolamide tablet therapy and at regular intervals during therapy. If significant changes occur, early discontinuance and institution of appropriate therapy are important. Periodic monitoring of serum electrolytes is recommended."],"adverse_reactions":["ADVERSE REACTIONS Body as a whole: Headache, malaise, fatigue, fever, flushing, growth retardation in children, flaccid paralysis, anaphylaxis Digestive: Gastrointestinal disturbances such as nausea, vomiting, diarrhea Hematological/Lymphatic: Blood dyscrasias such as aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia, thrombocytopenic purpura, melena Hepato-biliary disorders: Abnormal liver function, cholestatic jaundice, hepatic insufficiency, fulminant hepatic necrosis Metabolic/Nutritional: Metabolic acidosis, electrolyte imbalance, including hypokalemia, hyponatremia, osteomalacia with long-term phenytoin therapy, loss of appetite, taste alteration, hyper/hypoglycemia Nervous: Drowsiness, paraesthesia (including numbness and tingling of extremities and face), depression, excitement, ataxia, confusion, convulsions, dizziness Skin: Allergic skin reactions including urticaria, photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis Otologic : Hearing disturbances, tinnitus Eye Disorders: choroidal effusion, choroidal detachment, transient myopia. Transient myopia is the result of forward movement of the ciliary body leading to a narrowing of the angle. Urogenital: Crystalluria, increased risk of nephrolithiasis with long-term therapy, hematuria, glycosuria, renal failure, polyuria Postmarketing Experience: The following adverse reactions have been identified during post approval use of acetazolamide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Respiratory, thoracic and mediastinal disorders: Non-cardiogenic pulmonary edema has been reported following cataract surgery. To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Hypersensitivity to acetazolamide or any excipients in the formulation. Since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. Acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. It is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. Long-term administration of acetazolamide is contraindicated in patients with chronic noncongestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure."],"general_precautions":["General Increasing the dose does not increase the diuresis and may increase the incidence of drowsiness and/or paresthesia. Increasing the dose often results in a decrease in diuresis. Under certain circumstances, however, very large doses have been given in conjunction with other diuretics in order to secure diuresis in complete refractory failure. Choroidal effusion and choroidal detachment have been reported after the use of acetazolamide in the post-operative period following ophthalmic surgery. Discontinue acetazolamide tablets if choroidal effusion and/or choroidal detachment is suspected."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Acetazolamide is a potent carbonic anhydrase inhibitor, effective in the control of fluid secretion (eg, some types of glaucoma), in the treatment of certain convulsive disorders (eg, epilepsy) and in the promotion of diuresis in instances of abnormal fluid retention (eg, cardiac edema). Acetazolamide is not a mercurial diuretic. Rather, it is a nonbacteriostatic sulfonamide possessing a chemical structure and pharmacological activity distinctly different from the bacteriostatic sulfonamides. Acetazolamide is an enzyme inhibitor that acts specifically on carbonic anhydrase, the enzyme that catalyzes the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In the eye, this inhibitory action of acetazolamide decreases the secretion of aqueous humor and results in a drop in intraocular pressure, a reaction considered desirable in cases of glaucoma and even in certain nonglaucomatous conditions. Evidence seems to indicate that acetazolamide has utility as an adjuvant in the treatment of certain dysfunctions of the central nervous system (eg, epilepsy). Inhibition of carbonic anhydrase in this area appears to retard abnormal, paroxysmal, excessive discharge from central nervous system neurons. The diuretic effect of acetazolamide is due to its action in the kidney on the reversible reaction involving hydration of carbon dioxide and dehydration of carbonic acid. The result is renal loss of HCO 3 ion, which carries out sodium, water, and potassium. Alkalinization of the urine and promotion of diuresis are thus affected. Alteration in ammonia metabolism occurs due to increased reabsorption of ammonia by the renal tubules as a result of urinary alkalinization. Placebo-controlled clinical trials have shown that prophylactic administration of acetazolamide at a dose of 250 mg every eight to 12 hours (or a 500 mg controlled-release capsule once daily) before and during rapid ascent to altitude results in fewer and/or less severe symptoms (such as headache, nausea, shortness of breath, dizziness, drowsiness, and fatigue) of acute mountain sickness (AMS). Pulmonary function (eg, minute ventilation, expired vital capacity, and peak flow) is greater in the acetazolamide treated group, both in subjects with AMS and asymptomatic subjects. The acetazolamide treated climbers also had less difficulty in sleeping."],"indications_and_usage":["INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent."],"information_for_patients":["Information for Patients Adverse reactions common to all sulfonamide derivatives may occur: anaphylaxis, fever, rash (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), crystalluria, renal calculus, bone marrow depression, thrombocytopenic purpura, hemolytic anemia, leukopenia, pancytopenia, and agranulocytosis. Caution is advised for early detection of such reactions and the drug should be discontinued and appropriate therapy instituted. In patients with pulmonary obstruction or emphysema where alveolar ventilation may be impaired, acetazolamide, which may precipitate or aggravate acidosis, should be used with caution. Gradual ascent is desirable to try to avoid acute mountain sickness. If rapid ascent is undertaken and acetazolamide tablets are used, it should be noted that such use does not obviate the need for prompt descent if severe forms of high altitude sickness occur, ie, high altitude pulmonary edema (HAPE) or high altitude cerebral edema. Caution is advised for patients receiving concomitant high-dose aspirin and acetazolamide, as anorexia, tachypnea, lethargy, metabolic acidosis, coma, and death have been reported (see WARNINGS ). Both increases and decreases in blood glucose levels have been described in patients treated with acetazolamide. This should be taken into consideration in patients with impaired glucose tolerance or diabetes mellitus. Acetazolamide treatment may cause electrolyte imbalances, including hyponatremia and hypokalemia, as well as metabolic acidosis. Therefore, periodic monitoring of serum electrolytes is recommended. Particular caution is recommended in patients with conditions that are associated with, or predispose a patient to, electrolyte and acid/base imbalances, such as patients with impaired renal function (including elderly patients; see PRECAUTIONS, Geriatric Use ), patients with diabetes mellitus, and patients with impaired alveolar ventilation. Some adverse reactions to acetazolamide, such as drowsiness, fatigue, and myopia, may impair the ability to drive and operate machinery."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Glaucoma: Acetazolamide should be used as an adjunct to the usual therapy. The dosage employed in the treatment of chronic simple (open-angle) glaucoma ranges from 250 mg to 1 g of acetazolamide per 24 hours, usually in divided doses for amounts over 250 mg. It has usually been found that a dosage in excess of 1 g per 24 hours does not produce an increased effect. In all cases, the dosage should be adjusted with careful individual attention both to symptomatology and ocular tension. Continuous supervision by a physician is advisable. In treatment of secondary glaucoma and in the preoperative treatment of some cases of acute congestive (closed-angle) glaucoma , the preferred dosage is 250 mg every four hours, although some cases have responded to 250 mg twice daily on short-term therapy. In some acute cases, it may be more satisfactory to administer an initial dose of 500 mg followed by 125 or 250 mg every four hours depending on the individual case. A complementary effect has been noted when acetazolamide has been used in conjunction with miotics or mydriatics as the case demanded. Epilepsy: It is not clearly known whether the beneficial effects observed in epilepsy are due to direct inhibition of carbonic anhydrase in the central nervous system or whether they are due to the slight degree of acidosis produced by the divided dosage. The best results to date have been seen in petit mal in pediatric patients. Good results, however, have been seen in patients, both pediatric patients and adult, in other types of seizures such as grand mal, mixed seizure patterns, myoclonic jerk patterns, etc. The suggested total daily dose is 8 to 30 mg per kg in divided doses. Although some patients respond to a low dose, the optimum range appears to be from 375 to 1,000 mg daily. However, some investigators feel that daily doses in excess of 1 g do not produce any better results than a 1 g dose. When acetazolamide tablets are given in combination with other anticonvulsants, it is suggested that the starting dose should be 250 mg once daily in addition to the existing medications. This can be increased to levels as indicated above. The change from other medications to acetazolamide should be gradual and in accordance with usual practice in epilepsy therapy. Congestive Heart Failure: For diuresis in congestive heart failure, the starting dose is usually 250 to 375 mg once daily in the morning (5 mg/kg). If, after an initial response, the patient fails to continue to lose edema fluid, do not increase the dose but allow for kidney recovery by skipping medication for a day. Acetazolamide tablets yields best diuretic results when given on alternate days, or for two days alternating with a day of rest. Failures in therapy may be due to overdosage or too frequent dosage. The use of acetazolamide does not eliminate the need for other therapy such as digitalis, bed rest, and salt restriction. Drug-Induced Edema: Recommended dosage is 250 to 375 mg of acetazolamide once a day for one or two days, alternating with a day of rest. Acute Mountain Sickness: Dosage is 500 mg to 1,000 mg daily, in divided doses using tablets or sustained-release capsules as appropriate. In circumstances of rapid ascent, such as in rescue or military operations, the higher dose level of 1,000 mg is recommended. It is preferable to initiate dosing 24 to 48 hours before ascent and to continue for 48 hours while at high altitude, or longer as necessary to control symptoms. Note: The dosage recommendations for glaucoma and epilepsy differ considerably from those for congestive heart failure, since the first two conditions are not dependent upon carbonic anhydrase inhibition in the kidney which requires intermittent dosage if it is to recover from the inhibitory effect of the therapeutic agent. Interference with Laboratory Tests Sulfonamides may give false negative or decreased values for urinary phenolsulfonphthalein and phenol red elimination values for urinary protein, serum non-protein and for serum uric acid. Acetazolamide may produce an increased level of crystals in the urine. Acetazolamide interferes with the HPLC method of assay for theophylline. Interference with the theophylline assay by acetazolamide depends on the solvent used in the extraction; acetazolamide may not interfere with other assay methods for theophylline."],"spl_product_data_elements":["acetazolamide acetazolamide ACETAZOLAMIDE ACETAZOLAMIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POVIDONE STARCH, CORN SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO HP;287 acetazolamide acetazolamide ACETAZOLAMIDE ACETAZOLAMIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE POVIDONE STARCH, CORN SODIUM LAURYL SULFATE SODIUM STARCH GLYCOLATE TYPE A POTATO HP;288"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 125 MG (100 TABLETS) NDC 23155- 287 -01 AcetaZOLAMIDE Tablets, USP 125 mg 100 Tablets Rx Only label","PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 125 MG (1000 TABLETS) NDC 23155- 287 -10 AcetaZOLAMIDE Tablets, USP 125 mg 1000 Tablets Rx Only label 125 mg 1000 tablets","PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 250 MG (100 TABLETS) NDC 23155- 288 -01 AcetaZOLAMIDE Tablets, USP 250 mg 100 Tablets Rx Only label 250 mg 100 tablets","PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 250 MG (1000 TABLETS) NDC 23155- 288 -10 AcetaZOLAMIDE Tablets, USP 250 mg 1000 Tablets Rx Only label 250 mg 1000 tablets"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies in animals to evaluate the carcinogenic potential of acetazolamide have not been conducted. In a bacterial mutagenicity assay, acetazolamide was not mutagenic when evaluated with and without metabolic activation. The drug had no effect on fertility when administered in the diet to male and female rats at a daily intake of up to 4 times the recommended human dose of 1,000 mg in a 50 kg individual."]},"tags":[{"label":"Carbonic Anhydrase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Carbonic anhydrase","category":"target"},{"label":"CA1","category":"gene"},{"label":"CA12","category":"gene"},{"label":"CA13","category":"gene"},{"label":"S01EC01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Absence seizure","category":"indication"},{"label":"Angle-closure glaucoma","category":"indication"},{"label":"Anoxia due to high altitude","category":"indication"},{"label":"Edema","category":"indication"},{"label":"Malignant glaucoma","category":"indication"},{"label":"Open-angle glaucoma","category":"indication"},{"label":"Teva Branded Pharm","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Carbonic Anhydrase Inhibitors","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Diuretics","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"674 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"657 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"279 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"276 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"249 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"238 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"238 reports"},{"date":"","signal":"METABOLIC ACIDOSIS","source":"FDA FAERS","actionTaken":"195 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"190 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"169 reports"}],"drugInteractions":[{"url":"/drug/lithium","drug":"lithium","action":"Monitor closely","effect":"May interact with Lithium","source":"DrugCentral","drugSlug":"lithium"}],"commonSideEffects":[{"effect":"Metabolic acidosis","drugRate":"reported","severity":"serious"},{"effect":"Electrolyte imbalance","drugRate":"reported","severity":"serious"},{"effect":"Hepatic insufficiency","drugRate":"reported","severity":"serious"},{"effect":"Fulminant hepatic necrosis","drugRate":"reported","severity":"serious"},{"effect":"Aplastic anemia","drugRate":"reported","severity":"serious"},{"effect":"Agranulocytosis","drugRate":"reported","severity":"serious"},{"effect":"Toxic epidermal necrolysis","drugRate":"reported","severity":"serious"},{"effect":"Stevens-Johnson syndrome","drugRate":"reported","severity":"serious"},{"effect":"Convulsions","drugRate":"reported","severity":"serious"},{"effect":"Flaccid paralysis","drugRate":"reported","severity":"serious"},{"effect":"Photosensitivity","drugRate":"reported","severity":"mild"},{"effect":"Polyuria","drugRate":"reported","severity":"mild"},{"effect":"Drowsiness","drugRate":"reported","severity":"mild"},{"effect":"Confusion","drugRate":"reported","severity":"mild"},{"effect":"Urticaria","drugRate":"reported","severity":"mild"},{"effect":"Melena","drugRate":"reported","severity":"mild"},{"effect":"Hematuria","drugRate":"reported","severity":"mild"},{"effect":"Glycosuria","drugRate":"reported","severity":"mild"},{"effect":"Tinnitus","drugRate":"reported","severity":"mild"},{"effect":"Hearing dysfunction","drugRate":"reported","severity":"mild"},{"effect":"Loss of appetite","drugRate":"reported","severity":"mild"},{"effect":"Taste alteration","drugRate":"reported","severity":"mild"},{"effect":"Gastrointestinal disturbances","drugRate":"reported","severity":"mild"},{"effect":"Nausea","drugRate":"reported","severity":"mild"},{"effect":"Vomiting","drugRate":"reported","severity":"mild"},{"effect":"Diarrhea","drugRate":"reported","severity":"mild"},{"effect":"Paresthesias","drugRate":"reported","severity":"mild"},{"effect":"Transient myopia","drugRate":"reported","severity":"mild"}],"contraindications":["Acute nephropathy","Decreased respiratory function","Diabetes mellitus type 1","Diabetes mellitus type 2","Disease of blood AND/OR blood-forming organ","Disease of liver","Disorder of electrolytes","Gout","Hepatic failure","Hyperkalemia","Hyponatremia","Kidney disease","Metabolic acidosis, normal anion gap, acidifying salts","Primary adrenocortical insufficiency","Recurrent Calcium Renal Calculi","Renal tubular acidosis","Respiratory acidosis"],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies in pregnant women. Acetazolamide should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.","Geriatric use":"Metabolic acidosis, which can be severe, may occur in the elderly with reduced renal function.In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy.","Paediatric use":"The safety and effectiveness of acetaZOLAMIDE in children have not been established."}},"trials":[],"aliases":[],"company":"Teva","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1393/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$51","description":"ACETAZOLAMIDE 125 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACETAZOLAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:23:19.974668+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Acetazolamide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:23:27.105905+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:23:25.712295+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:23:19.165841+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETAZOLAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:23:26.023435+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:17.902027+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:17.902065+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:58.221875+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:17.902078+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:23:27.533685+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Carbonic anhydrase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:27.105863+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL20/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:23:26.749744+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA205530","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:23:17.902084+00:00"}},"allNames":"diamox","offLabel":[],"synonyms":["acetazolamide","acetamox","acetazolamid","cidamex","nephramide","acetazolamide sodium"],"timeline":[{"date":"1953-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from TEVA BRANDED PHARM to Teva Branded Pharm"},{"date":"1953-07-27","type":"positive","source":"DrugCentral","milestone":"FDA approval (Teva Branded Pharm)"}],"aiSummary":"Diamox (Acetazolamide) is a small molecule carbonic anhydrase inhibitor developed by TEVA BRANDED PHARM and currently owned by the same company. It targets carbonic anhydrase to treat various conditions, including absence seizures, glaucoma, anoxia due to high altitude, and edema. Diamox has been FDA-approved since 1953 and is available as a generic medication due to its off-patent status. The drug has a half-life of 13.0 hours and high bioavailability of 99%. It is used to treat a range of conditions, including those related to fluid retention and high altitude.","brandName":"Diamox","ecosystem":[{"indication":"Absence seizure","otherDrugs":[{"name":"clonazepam","slug":"clonazepam","company":"Roche"},{"name":"ethosuximide","slug":"ethosuximide","company":"Parke Davis"},{"name":"lorazepam","slug":"lorazepam","company":"Valeant Intl"},{"name":"methsuximide","slug":"methsuximide","company":"Parke Davis"}],"globalPrevalence":null},{"indication":"Angle-closure glaucoma","otherDrugs":[{"name":"dichlorophen","slug":"dichlorophen","company":""},{"name":"dichlorphenamide","slug":"dichlorphenamide","company":""},{"name":"methazolamide","slug":"methazolamide","company":"Lederle"}],"globalPrevalence":null},{"indication":"Anoxia due to high altitude","otherDrugs":[],"globalPrevalence":null},{"indication":"Edema","otherDrugs":[{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"},{"name":"chlortalidone","slug":"chlortalidone","company":""}],"globalPrevalence":200000},{"indication":"Malignant glaucoma","otherDrugs":[],"globalPrevalence":null},{"indication":"Open-angle glaucoma","otherDrugs":[{"name":"apraclonidine","slug":"apraclonidine","company":"Alcon"},{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""},{"name":"brimonidine","slug":"brimonidine","company":""}],"globalPrevalence":null},{"indication":"Peripheral Edema due to Chronic Heart Failure","otherDrugs":[{"name":"bumetanide","slug":"bumetanide","company":""},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"},{"name":"chlortalidone","slug":"chlortalidone","company":""},{"name":"ethacrynic acid","slug":"ethacrynic-acid","company":"Aton"}],"globalPrevalence":64000000},{"indication":"Peripheral edema","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Carbonic anhydrase","novelty":"First-in-class","targets":[{"gene":"CA1","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 1"},{"gene":"CA12","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 12"},{"gene":"CA13","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 13"},{"gene":"CA14","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 14"},{"gene":"CA2","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 2"},{"gene":"CA3","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 3"},{"gene":"CA4","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 4"},{"gene":"CA5A","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 5A, mitochondrial"},{"gene":"CA5B","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 5B, mitochondrial"},{"gene":"CA6","source":"DrugCentral","target":"Carbonic anhydrase","protein":"Carbonic anhydrase 6"}],"moaClass":"Carbonic Anhydrase Inhibitors","modality":"Small Molecule","drugClass":"Carbonic Anhydrase Inhibitor [EPC]","explanation":"","oneSentence":"","technicalDetail":"Diamox inhibits the enzyme carbonic anhydrase (CA) by competing with the substrate carbon dioxide (CO2) for binding to the enzyme's active site, thereby reducing the enzyme's activity and subsequent production of bicarbonate (HCO3-) and hydrogen ions (H+)."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Acetazolamide","title":"Acetazolamide","extract":"Acetazolamide, sold under the trade name Diamox among others, is a medication used to treat glaucoma, epilepsy, acute mountain sickness, periodic paralysis, idiopathic intracranial hypertension, heart failure and to alkalinize urine. It may be used long term for the treatment of open angle glaucoma and short term for acute angle closure glaucoma until surgery can be carried out. It is taken by mouth or injection into a vein. Acetazolamide is a first generation carbonic anhydrase inhibitor and it decreases the ocular fluid and osmolality in the eye to decrease intraocular pressure.","wiki_history":"==History==\nAn early description of this compound (as 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide) and its synthesis has been patented in 1951."},"commercial":{"launchDate":"1953","_launchSource":"DrugCentral (FDA 1953-07-27, TEVA BRANDED PHARM)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/56","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ACETAZOLAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACETAZOLAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Acetazolamide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T07:28:12.140343","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:23:58.371945+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"dichlorphenamide","drugSlug":"dichlorphenamide","fdaApproval":"1958-07-22","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"dorzolamide","drugSlug":"dorzolamide","fdaApproval":"1994-12-09","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"brinzolamide","drugSlug":"brinzolamide","fdaApproval":"1998-04-01","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methazolamide","drugSlug":"methazolamide","fdaApproval":"1959-01-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"acetazolamide","indications":{"approved":[{"id":"acetazolamide-edema-due-to-congestive-heart-","name":"Edema due to congestive heart failure","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with edema due to congestive heart failure","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with edema due to congestive heart failure","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-drug-induced-edema","name":"Drug-induced edema","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with drug-induced edema","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with drug-induced edema","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-centrencephalic-epilepsies","name":"Centrencephalic epilepsies","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with centrencephalic epilepsies (petit mal, unlocalized seizures)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with centrencephalic epilepsies (petit mal, unlocalized seizures)","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-chronic-simple-(open-angle)-gl","name":"Chronic simple (open-angle) glaucoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with chronic simple (open-angle) glaucoma","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with chronic simple (open-angle) glaucoma","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-secondary-glaucoma","name":"Secondary glaucoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with secondary glaucoma","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with secondary glaucoma","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-preoperative-acute-angle-closu","name":"Preoperative acute angle-closure glaucoma","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with acute angle-closure glaucoma requiring preoperative lowering of intraocular pressure","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with acute angle-closure glaucoma requiring preoperative lowering of intraocular pressure","diagnosticRequired":null,"brandNameForIndication":"Diamox"},{"id":"acetazolamide-acute-mountain-sickness-preven","name":"Acute mountain sickness prevention","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Climbers attempting rapid ascent and those very susceptible to acute mountain sickness despite gradual ascent","pivotalTrial":null,"restrictions":[],"patientPopulation":"Climbers attempting rapid ascent and those very susceptible to acute mountain sickness despite gradual ascent","diagnosticRequired":null,"brandNameForIndication":"Diamox"}],"offLabel":[{"name":"Benign intracranial hypertension","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":516,"evidenceLevel":"strong"},{"name":"Epilepsy","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":321,"evidenceLevel":"strong"},{"name":"Familial hypokalemic periodic paralysis","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Familial periodic paralysis","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":108,"evidenceLevel":"strong"},{"name":"Hydrocephalus due to Intraventricular Hemorrhage","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Idiopathic intracranial hypertension","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Metabolic alkalosis","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":181,"evidenceLevel":"strong"},{"name":"Mixed Epilepsy","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Myoclonic seizure","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":206,"evidenceLevel":"strong"},{"name":"Obstructive hydrocephalus","source":"DrugCentral","drugName":"ACETAZOLAMIDE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Simple partial seizure","source":"DrugCentral","drugName":"ACETAZOLAMIDE"},{"name":"Tonic-clonic epilepsy","source":"DrugCentral","drugName":"ACETAZOLAMIDE"},{"name":"Urine Alkalinization","source":"DrugCentral","drugName":"ACETAZOLAMIDE"}],"pipeline":[]},"currentOwner":"Teva Branded Pharm","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"dichlorphenamide","brandName":"dichlorphenamide","genericName":"dichlorphenamide","approvalYear":"1958","relationship":"same-class"},{"drugId":"dorzolamide","brandName":"dorzolamide","genericName":"dorzolamide","approvalYear":"1994","relationship":"same-class"},{"drugId":"brinzolamide","brandName":"brinzolamide","genericName":"brinzolamide","approvalYear":"1998","relationship":"same-class"},{"drugId":"methazolamide","brandName":"methazolamide","genericName":"methazolamide","approvalYear":"1959","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06060613","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":["Tumor Skin","Metastatic Melanoma","Melanoma","Lung Cancer","Metastatic Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer"],"enrollment":208,"completionDate":"2028-06-30"},{"nctId":"NCT07482072","phase":"","title":"Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03","conditions":["Alzheimer Dementia (AD)","Diabete Type 2"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT07469722","phase":"PHASE2,PHASE3","title":"POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2026-03-23","conditions":["Acute Heart Failure (AHF)","Congestive Heart Failure Acute","Diuretic Effect","Lung Ultrasonography Score","Ultrasonography, Doppler","Point-of-care Ultrasound (POCUS)"],"enrollment":128,"completionDate":"2028-07-01"},{"nctId":"NCT04118387","phase":"PHASE4","title":"Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-01-07","conditions":["Sleep Disordered Breathing","Able Bodied"],"enrollment":200,"completionDate":"2026-12-31"},{"nctId":"NCT06043830","phase":"PHASE2","title":"Managing Opioid Related Sleep Apnea With Acetazolamide","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-10-18","conditions":["Sleep-Disordered Breathing","Obstructive Sleep Apnea","Central Sleep Apnea","Chronic Pain","Opioid Use"],"enrollment":39,"completionDate":"2025-12-23"},{"nctId":"NCT06945848","phase":"NA","title":"Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-01-05","conditions":["Idiopathic Intracranial Hypertension (IIH)"],"enrollment":114,"completionDate":"2030-01-05"},{"nctId":"NCT07101250","phase":"PHASE4","title":"Preoperative Acetazolamide","status":"RECRUITING","sponsor":"Prisma Health-Upstate","startDate":"2025-10-30","conditions":["Post Operative Pain","Laparoscopic Hysterectomy","Referred Pain"],"enrollment":100,"completionDate":"2026-11-01"},{"nctId":"NCT05707442","phase":"PHASE3","title":"Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-02-16","conditions":["Idiopathic Intracranial Hypotension","Venous Sinus Stenosis"],"enrollment":74,"completionDate":"2027-03"},{"nctId":"NCT07372040","phase":"PHASE2","title":"Add-on Diuretics in Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"Tanta University","startDate":"2026-02-01","conditions":["Acute Decompensated Heart Failure"],"enrollment":66,"completionDate":"2027-02-01"},{"nctId":"NCT06499727","phase":"PHASE4","title":"HighCycle Study: Effect of Acetazolamide on Acute Mountain Sickness in Women Compared to Men","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2024-07-15","conditions":["Acute Mountain Sickness"],"enrollment":303,"completionDate":"2025-08-31"},{"nctId":"NCT03467360","phase":"PHASE1","title":"Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma","status":"RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2019-08-02","conditions":["Small Cell Lung Cancer"],"enrollment":27,"completionDate":"2027-04-27"},{"nctId":"NCT05589792","phase":"PHASE1,PHASE2","title":"Acetazolamide on REM OSA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2023-01-30","conditions":["Obstructive Sleep Apnea"],"enrollment":11,"completionDate":"2025-12-31"},{"nctId":"NCT06285760","phase":"","title":"Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","status":"RECRUITING","sponsor":"Puerta de Hierro University Hospital","startDate":"2024-03-01","conditions":["Heart Failure","Persistent Congestion"],"enrollment":64,"completionDate":"2026-12-31"},{"nctId":"NCT03921827","phase":"NA","title":"External Counterpulsation Therapy for Severe Steno-occlusive Intracranial Stenosis","status":"COMPLETED","sponsor":"National University of Singapore","startDate":"2019-01-08","conditions":["Ischemic Stroke"],"enrollment":130,"completionDate":"2024-11-30"},{"nctId":"NCT05616260","phase":"PHASE2","title":"Acetazolamide for Obstructive Sleep Apnea to Improve Heart Health","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2022-12-02","conditions":["Obstructive Sleep Apnea"],"enrollment":54,"completionDate":"2025-05-13"},{"nctId":"NCT05470283","phase":"PHASE1","title":"Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-07","conditions":["Tumor","Metastatic Melanoma","Melanoma"],"enrollment":21,"completionDate":"2027-04-01"},{"nctId":"NCT06521476","phase":"PHASE2","title":"Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder","status":"RECRUITING","sponsor":"Sanjay R Patel","startDate":"2025-09-30","conditions":["Central Sleep Apnea Comorbid With Opioid Use"],"enrollment":40,"completionDate":"2028-02"},{"nctId":"NCT06776432","phase":"PHASE2","title":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","status":"RECRUITING","sponsor":"Shionogi Apnimed Sleep Science","startDate":"2025-04-02","conditions":["Sleep Apnea"],"enrollment":60,"completionDate":"2025-12"},{"nctId":"NCT00262470","phase":"PHASE1,PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":["Tachycardia","Chronic Orthostatic Intolerance"],"enrollment":150,"completionDate":"2029-12"},{"nctId":"NCT07199088","phase":"NA","title":"Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure","status":"RECRUITING","sponsor":"University of Health Sciences Lahore","startDate":"2025-10-11","conditions":["Acute Decompensated Heart Failure","Heart Failure, Diastolic","Heart Failure, Systolic"],"enrollment":320,"completionDate":"2026-10-30"},{"nctId":"NCT06919744","phase":"NA","title":"Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2025-09-19","conditions":["Idiopathic Intracranial Hypertension (IIH)"],"enrollment":114,"completionDate":"2029-04-30"},{"nctId":"NCT04726982","phase":"PHASE4","title":"Optimal Dosage of Acetazolamide for OSA Treatment","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2021-04-20","conditions":["Obstructive Sleep Apnea"],"enrollment":91,"completionDate":"2024-05-05"},{"nctId":"NCT02703220","phase":"PHASE4","title":"Sleep Apnea in Elderly","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2015-07-03","conditions":["Sleep Apnea","Elderly Adults"],"enrollment":100,"completionDate":"2026-07-31"},{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":["Glaucoma"],"enrollment":28,"completionDate":"2024-10-04"},{"nctId":"NCT07118462","phase":"PHASE4","title":"HighCycle Study: Acetazolamide, High Altitude and Plasma Volume","status":"RECRUITING","sponsor":"Centre d'Expertise sur l'Altitude EXALT","startDate":"2024-07-15","conditions":["High Altitude Effects","High Altitude Hypoxia","Acute Mountain Sickness (AMS)","Plasma Volume","Women"],"enrollment":270,"completionDate":"2025-12-31"},{"nctId":"NCT05411991","phase":"PHASE4","title":"Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment","status":"COMPLETED","sponsor":"Vrije Universiteit Brussel","startDate":"2022-06-12","conditions":["Acute Heart Failure","Diuretics Drug Reactions"],"enrollment":107,"completionDate":"2024-07-01"},{"nctId":"NCT06092437","phase":"NA","title":"Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients","status":"RECRUITING","sponsor":"Zuyderland Medisch Centrum","startDate":"2023-02-27","conditions":["Heart Failure Acute"],"enrollment":466,"completionDate":"2026-08-27"},{"nctId":"NCT04251364","phase":"NA","title":"Treatment of Chronic Mountain Sickness","status":"COMPLETED","sponsor":"Centre d'Expertise sur l'Altitude EXALT","startDate":"2020-02-15","conditions":["Hypoxia, Altitude"],"enrollment":60,"completionDate":"2021-12-30"},{"nctId":"NCT05589753","phase":"PHASE1,PHASE2","title":"Sleep Disordered Breathing With Opioid Use","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-05-02","conditions":["Sleep Apnea","Opioid Use","Sleep Disordered Breathing"],"enrollment":150,"completionDate":"2027-03-31"},{"nctId":"NCT05953610","phase":"PHASE2","title":"Endotypic Traits and Obstructive Sleep Apnea Surgery","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2024-01-07","conditions":["Obstructive Sleep Apnea"],"enrollment":150,"completionDate":"2028-08-31"},{"nctId":"NCT06981234","phase":"PHASE2","title":"Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-08-14","conditions":["Type 1 Diabetes"],"enrollment":25,"completionDate":"2027-06"},{"nctId":"NCT06499714","phase":"","title":"HighCycle Study: Effect of High Altitude on Acute Mountain Sickness in Women Related to Their Menstrual Cycle Phase","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2024-07-15","conditions":["Acute Mountain Sickness"],"enrollment":90,"completionDate":"2025-12-31"},{"nctId":"NCT06498544","phase":"","title":"HighCycle Study: Effect of High Altitude on Sleep Disordered Breathing in Women Related to Their Menstrual Cycle Phase","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2024-07-15","conditions":["Sleep-Disordered Breathing"],"enrollment":90,"completionDate":"2025-12-31"},{"nctId":"NCT06498505","phase":"PHASE4","title":"HighCycle: Effect of Acetazolamide on Pulmonary Artery Pressure in Women Compared to Men","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2024-07-15","conditions":["High Altitude"],"enrollment":270,"completionDate":"2025-12-31"},{"nctId":"NCT06498531","phase":"PHASE4","title":"HighCycle Study: Effect of Acetazolamide on Sleep Disordered Breathing in Women Compared to Men","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2024-07-15","conditions":["Sleep-Disordered Breathing"],"enrollment":270,"completionDate":"2025-12-31"},{"nctId":"NCT06114537","phase":"PHASE2","title":"The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-01-20","conditions":["Retinoschisis"],"enrollment":19,"completionDate":"2024-09-13"},{"nctId":"NCT05473364","phase":"PHASE1,PHASE2","title":"Acetazolamide in Persons With Type 1 Diabetes - Dose Finding","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2023-03-20","conditions":["Type 1 Diabetes"],"enrollment":12,"completionDate":"2024-07-31"},{"nctId":"NCT03011671","phase":"PHASE1","title":"Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2018-10-03","conditions":["Malignant Glioma of Brain"],"enrollment":10,"completionDate":"2025-03-14"},{"nctId":"NCT06146101","phase":"PHASE2,PHASE3","title":"RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incannex Healthcare Ltd","startDate":"2024-05-02","conditions":["Obstructive Sleep Apnea"],"enrollment":560,"completionDate":"2026-12"},{"nctId":"NCT06913712","phase":"","title":"BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment","status":"RECRUITING","sponsor":"University of Valencia","startDate":"2024-06-27","conditions":["Idiopathic Intracranial Hypertension (IIH)"],"enrollment":25,"completionDate":"2027-04-01"},{"nctId":"NCT04887792","phase":"PHASE1,PHASE2","title":"Acetazolamide for Treatment Resistant Schizophrenia","status":"RECRUITING","sponsor":"Vishwajit Nimgaonkar, MD PhD","startDate":"2022-02-01","conditions":["Schizophrenia","Schizo Affective Disorder"],"enrollment":60,"completionDate":"2026-12-30"},{"nctId":"NCT05780619","phase":"","title":"Diagnostic Performance of the Resistance Index (RI) for the Assessment of Cerebral Vasoreactivity in Transcranial Doppler","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-06-09","conditions":["Stenosis","Occlusion"],"enrollment":77,"completionDate":"2029-06"},{"nctId":"NCT02945527","phase":"PHASE2,PHASE3","title":"Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)","status":"TERMINATED","sponsor":"Universidad Peruana Cayetano Heredia","startDate":"2015-12-04","conditions":["Neurocysticercosis"],"enrollment":4,"completionDate":"2018-12"},{"nctId":"NCT04975269","phase":"PHASE2","title":"Acetazolamide Trial in Normal Pressure Hydrocephalus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Uppsala University Hospital","startDate":"2022-02-17","conditions":["Idiopathic Normal Pressure Hydrocephalus (INPH)"],"enrollment":50,"completionDate":"2025-12-31"},{"nctId":"NCT05300477","phase":"PHASE4","title":"Pharmacological Countermeasures for High Altitude","status":"ACTIVE_NOT_RECRUITING","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2022-05-27","conditions":["Hypobaric Hypoxia"],"enrollment":18,"completionDate":"2025-09-30"},{"nctId":"NCT04679389","phase":"PHASE2,PHASE3","title":"Acetazolamide Efficacy in Ataxia in PMM2-CDG","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-03-17","conditions":["Pmm2-CDG","CDG1A"],"enrollment":25,"completionDate":"2024-01-24"},{"nctId":"NCT06362668","phase":"NA","title":"EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)","status":"COMPLETED","sponsor":"Reprieve Cardiovascular, Inc","startDate":"2024-05-17","conditions":["Acute Decompensated Heart Failure"],"enrollment":12,"completionDate":"2024-10-31"},{"nctId":"NCT06166654","phase":"PHASE4","title":"Optimal Diuretic Therapies for Acute Heart Failure With Volume Overload","status":"RECRUITING","sponsor":"Johannes Grand","startDate":"2024-09-05","conditions":["Acute Heart Failure"],"enrollment":939,"completionDate":"2027-09-30"},{"nctId":"NCT05986773","phase":"PHASE4","title":"Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance","status":"TERMINATED","sponsor":"Stadtspital Zürich","startDate":"2023-10-10","conditions":["Acute Heart Failure","Diuretic Resistance"],"enrollment":13,"completionDate":"2024-12-31"},{"nctId":"NCT06783166","phase":"PHASE2,PHASE3","title":"Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure","status":"RECRUITING","sponsor":"Mansoura University","startDate":"2024-08-15","conditions":["Acute Heart Failure"],"enrollment":100,"completionDate":"2025-08-01"},{"nctId":"NCT05857384","phase":"PHASE1","title":"Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs","status":"COMPLETED","sponsor":"Incannex Healthcare Ltd","startDate":"2023-09-08","conditions":["Obstructive Sleep Apnea"],"enrollment":125,"completionDate":"2024-07-31"},{"nctId":"NCT05804084","phase":"PHASE2","title":"Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-05-16","conditions":["Obstructive Sleep Apnea"],"enrollment":60,"completionDate":"2026-10-31"},{"nctId":"NCT05802849","phase":"PHASE4","title":"Acetazolamide Per os for Decompensation of Heart Failure","status":"RECRUITING","sponsor":"Samara State Medical University","startDate":"2023-05-01","conditions":["Chronic Heart Failure"],"enrollment":400,"completionDate":"2025-12-01"},{"nctId":"NCT03715972","phase":"","title":"Cerebrovascular Reserve and White Matter Disease in Patients with Chronic Anemia","status":"COMPLETED","sponsor":"Children's Hospital Los Angeles","startDate":"2018-07-15","conditions":["Thalassemia","Sickle Cell Disease","Healthy Controls"],"enrollment":165,"completionDate":"2022-12-31"},{"nctId":"NCT03505788","phase":"PHASE4","title":"Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)","status":"COMPLETED","sponsor":"Ziekenhuis Oost-Limburg","startDate":"2018-11-11","conditions":["Acute Decompensated Heart Failure","Volume Overload"],"enrollment":519,"completionDate":"2022-05-16"},{"nctId":"NCT06475105","phase":"PHASE4","title":"Combination Oral Acetazolamide and Intravenous Furosemide on Acute Decompensated Heart Failure Outcomes","status":"RECRUITING","sponsor":"Universitas Diponegoro","startDate":"2024-04-20","conditions":["Acute Decompensated Heart Failure"],"enrollment":66,"completionDate":"2024-12-31"},{"nctId":"NCT06624267","phase":"","title":"Test of Reproducibility of [15O]H20-PET Assessment of Brain Perfusion","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-11","conditions":["Microvascular Disease","Microvascular Complications","Diabetes Mellitus Type 2","Cerebral Hypoperfusion","Dementia"],"enrollment":8,"completionDate":"2027-12"},{"nctId":"NCT06628297","phase":"","title":"Comparison of Differencens in VO2-max, Perfusion of the Heart and Brain and Cognitive Performance Between Patients with Type 2 Diabetes and Healthy Age Matched Controls.","status":"NOT_YET_RECRUITING","sponsor":"University Hospital Bispebjerg and Frederiksberg","startDate":"2024-11","conditions":["Microvascular Disease","Microvascular Complications","Dementia","Diabetes Mellitus Type 2","Cerebral Hypoperfusion"],"enrollment":72,"completionDate":"2027-12"},{"nctId":"NCT06330818","phase":"NA","title":"Imaging in Moyamoya Disease - Study to Investigate Different Imaging Technologies for a Better Understanding of Various Imaging Techniques to Evaluate Cerebral Hemodynamics, Disease-activity and Possibly the Etiology in Moyamoya Patients","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2024-07-01","conditions":["Moyamoya Disease","Moyamoya"],"enrollment":50,"completionDate":"2027-11-30"},{"nctId":"NCT06584747","phase":"NA","title":"Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy","status":"NOT_YET_RECRUITING","sponsor":"Centre Antoine Lacassagne","startDate":"2024-10","conditions":["Cerebrovascular Circulation"],"enrollment":22,"completionDate":"2026-10"},{"nctId":"NCT06535529","phase":"PHASE3","title":"Acetazolamide Versus Dapagliflozin in Acute Decompensated Heart Failure Patients","status":"RECRUITING","sponsor":"Helwan University","startDate":"2024-08-24","conditions":["Acute Decompensated Heart Failure"],"enrollment":60,"completionDate":"2025-09-01"},{"nctId":"NCT06414759","phase":"PHASE4","title":"Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload","status":"RECRUITING","sponsor":"Cairo University","startDate":"2024-07-01","conditions":["Acute Decompensated Heart Failure","Volume Overload","Edema"],"enrollment":110,"completionDate":"2025-03-30"},{"nctId":"NCT04227093","phase":"PHASE4","title":"Acetazolamide Add-On Therapy to OSA Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2020-01-22","conditions":["Obstructive Sleep Apnea"],"enrollment":26,"completionDate":"2024-08"},{"nctId":"NCT05293600","phase":"PHASE1,PHASE2","title":"Rescue Pharmacotherapy for OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-07-01","conditions":["Obstructive Sleep Apnea"],"enrollment":70,"completionDate":"2026-10-30"},{"nctId":"NCT04639193","phase":"PHASE2","title":"Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2020-12-01","conditions":["OSA","Obstructive Sleep Apnea"],"enrollment":20,"completionDate":"2022-01-27"},{"nctId":"NCT05904808","phase":"PHASE4","title":"The Heart Failure Diuresis Efficacy Comparison (DEA-HF) Study","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2023-04-19","conditions":["Chronic Heart Failure","Diuretics Drug Reactions","Congestive Heart Failure"],"enrollment":42,"completionDate":"2023-08-24"},{"nctId":"NCT06110078","phase":"EARLY_PHASE1","title":"Carbonic Anhydrase Inhibitors and Carbonation: A Novel Approach to Reduce Soda Consumption","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arizona","startDate":"2024-01-18","conditions":["Obesity"],"enrollment":44,"completionDate":"2024-05-01"},{"nctId":"NCT06273397","phase":"NA","title":"Acetazolamide or Metolazone in Acute Heart Failure","status":"NOT_YET_RECRUITING","sponsor":"Clinica Alemana de Santiago","startDate":"2024-05-01","conditions":["Heart Failure Acute","Decompensated Heart Failure"],"enrollment":1050,"completionDate":"2027-05-01"},{"nctId":"NCT05575180","phase":"PHASE4","title":"Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance","status":"COMPLETED","sponsor":"University of Waterloo","startDate":"2023-08-11","conditions":["High Altitude Effects"],"enrollment":15,"completionDate":"2024-02-22"},{"nctId":"NCT06091085","phase":"PHASE1,PHASE2","title":"Acetazolamide as a Means to Mitigate Falling Ventilatory Drive and Drive-dependent OSA","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-01-31","conditions":["OSA"],"enrollment":36,"completionDate":"2027-12-31"},{"nctId":"NCT03806751","phase":"EARLY_PHASE1","title":"A Noninvasive Arterial Input Estimation Method for O-15 PET and Integrated PET/MR Scanning","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-01","conditions":["Validation of a New Noninvasive Method to Obtain the Arterial Input Function (AIF) Directly by PET Imaging"],"enrollment":0,"completionDate":"2027-02-01"},{"nctId":"NCT05940220","phase":"PHASE3","title":"Efficacy of Oral Acetazolamide in Decongestion in Patients With Heart Failure","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2023-12-30","conditions":["Heart Failure"],"enrollment":130,"completionDate":"2025-10-10"},{"nctId":"NCT03377049","phase":"PHASE4","title":"Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2019-07-28","conditions":["Subarachnoid Hemorrhage, Aneurysmal","Vasospasm, Cerebral"],"enrollment":11,"completionDate":"2022-07-15"},{"nctId":"NCT02466074","phase":"PHASE2","title":"Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2016-08-17","conditions":["Multiple Sclerosis"],"enrollment":5,"completionDate":"2022-02-07"},{"nctId":"NCT03540914","phase":"PHASE4","title":"Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2018-06-01","conditions":["Altitude Hypoxia"],"enrollment":400,"completionDate":"2024-12-31"},{"nctId":"NCT04913389","phase":"PHASE3","title":"Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2021-06-01","conditions":["Chronic Obstructive Pulmonary Disease","Altitude Sickness","Altitude Hypoxia"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":["Cerebral Vein Thrombosis"],"enrollment":71,"completionDate":"2020-03-01"},{"nctId":"NCT03537924","phase":"PHASE4","title":"Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2018-06-01","conditions":["Altitude Hypoxia"],"enrollment":100,"completionDate":"2022-12-31"},{"nctId":"NCT03539367","phase":"PHASE4","title":"Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2018-06-01","conditions":["Altitude Hypoxia"],"enrollment":100,"completionDate":"2022-12-31"},{"nctId":"NCT04915365","phase":"PHASE3","title":"Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders With COPD Traveling to High Altitude","status":"UNKNOWN","sponsor":"University of Zurich","startDate":"2021-05-01","conditions":["Right Heart Function","Chronic Obstructive Pulmonary Disease","Altitude Sickness"],"enrollment":100,"completionDate":"2023-12-31"},{"nctId":"NCT05023941","phase":"PHASE4","title":"Optimization Strategy for the Prevention of AMS by RIPC Combined With Acetazolamide","status":"COMPLETED","sponsor":"Ji Xunming,MD,PhD","startDate":"2021-12-01","conditions":["Acute Mountain Sickness"],"enrollment":252,"completionDate":"2022-08-30"},{"nctId":"NCT04470843","phase":"PHASE1","title":"Impact of Acetazolamide in Reducing Referred Postoperative Pain","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-08-22","conditions":["Prostate Cancer","Men"],"enrollment":33,"completionDate":"2021-03-31"},{"nctId":"NCT05443308","phase":"","title":"Cerebral Vascular Reserve in Small Vessel Disease and Alzheimers Disease","status":"UNKNOWN","sponsor":"Bispebjerg Hospital","startDate":"2022-06-21","conditions":["Alzheimer Disease","Dementia, Vascular"],"enrollment":50,"completionDate":"2023-04-15"},{"nctId":"NCT03501966","phase":"PHASE3","title":"Surgical Idiopathic Intracranial Hypertension Treatment Trial","status":"TERMINATED","sponsor":"Jaeb Center for Health Research","startDate":"2019-02-06","conditions":["Idiopathic Intracranial Hypertension"],"enrollment":7,"completionDate":"2019-08-28"},{"nctId":"NCT05290948","phase":"PHASE2","title":"Comparison of Combined Intravitreal Bevacizumab and Oral Acetazolamide Versus Intravitreal Bevacizumab Alone for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2022-03-12","conditions":["Macular Edema"],"enrollment":57,"completionDate":"2022-12-01"},{"nctId":"NCT04351061","phase":"PHASE2","title":"Acetazolamide for the Prevention of Post Operative CSF Leak","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2020-05-07","conditions":["Cerebrospinal Fluid Leak"],"enrollment":0,"completionDate":"2021-11-24"},{"nctId":"NCT03536507","phase":"PHASE4","title":"Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-15","conditions":["Altitude Hypoxia"],"enrollment":185,"completionDate":"2018-08-02"},{"nctId":"NCT03540901","phase":"PHASE4","title":"Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-22","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":112,"completionDate":"2018-08-02"},{"nctId":"NCT03536429","phase":"PHASE4","title":"Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-15","conditions":["Altitude Hypoxia"],"enrollment":99,"completionDate":"2018-08-02"},{"nctId":"NCT03177811","phase":"PHASE4","title":"Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2017-05-24","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":127,"completionDate":"2018-08-02"},{"nctId":"NCT03536520","phase":"PHASE4","title":"Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-15","conditions":["Altitude Hypoxia"],"enrollment":59,"completionDate":"2018-08-02"},{"nctId":"NCT03536455","phase":"PHASE4","title":"Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-15","conditions":["Altitude Hypoxia"],"enrollment":92,"completionDate":"2018-08-02"},{"nctId":"NCT04907123","phase":"PHASE3","title":"Systematic Escalation of diuREtics With Natriuresis in Heart Failure Patients: SERENA Trial","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2021-10","conditions":["Heart Failure"],"enrollment":198,"completionDate":"2025-01"},{"nctId":"NCT03561675","phase":"PHASE4","title":"Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-05-15","conditions":["Acute Mountain Sickness"],"enrollment":349,"completionDate":"2019-08-31"},{"nctId":"NCT02755298","phase":"PHASE2,PHASE3","title":"Chronic Clinical Effect of Acetazolamide","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2016-10","conditions":["Hypertension, Pulmonary"],"enrollment":24,"completionDate":"2020-11"},{"nctId":"NCT00120731","phase":"NA","title":"Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones","status":"WITHDRAWN","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2005-07","conditions":["Kidney Calculi"],"enrollment":0,"completionDate":"2007-05"},{"nctId":"NCT04611373","phase":"PHASE3","title":"Clinical Study on the Efficacy of Acetazolamide Combined With Levamisole in the Treatment of HCC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2020-05-01","conditions":["HCC"],"enrollment":50,"completionDate":"2021-05-31"},{"nctId":"NCT02904265","phase":"PHASE2,PHASE3","title":"Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2016-09","conditions":["Landau-Kleffner Syndrome","Status Epilepticus, Electrographic"],"enrollment":3,"completionDate":"2019-07-26"},{"nctId":"NCT02902133","phase":"PHASE2","title":"Acetazolamide to Prevent Post Operative CSF Leak","status":"WITHDRAWN","sponsor":"University of Miami","startDate":"2016-09-01","conditions":["Cerebrospinal Fluid Leak"],"enrollment":0,"completionDate":"2021-09-01"},{"nctId":"NCT03828474","phase":"PHASE1","title":"Sickness Evaluation at Altitude With Acetazolamide at Relative Doses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-08-09","conditions":["Acute Mountain Sickness"],"enrollment":108,"completionDate":"2019-09-29"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Injection, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"ACETAZOLAMIDE EXTENDED-RELEASE"},{"form":"CAPSULE","route":"ORAL","productName":"acetazolamide"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"Acetazolamide"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","productName":"acetazolamide"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"AcetaZOLAMIDE"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Acetazolamide"},{"form":"TABLET","route":"ORAL","productName":"ACETAZOLAMIDE"},{"form":"TABLET","route":"ORAL","productName":"AcetaZOLAMIDE"},{"form":"TABLET","route":"ORAL","productName":"Acetazolamide"},{"form":"TABLET","route":"ORAL","productName":"acetaZOLAMIDE"},{"form":"TABLET","route":"ORAL","productName":"acetazolamide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146250","MMSL":"2596","NDDF":"002286","UNII":"O3FX965V0I","VUID":"4017898","CHEBI":"CHEBI:27690","VANDF":"4017898","INN_ID":"481","RXNORM":"167","UMLSCUI":"C0000981","chemblId":"CHEMBL20","ChEMBL_ID":"CHEMBL20","KEGG_DRUG":"D00218","DRUGBANK_ID":"DB00819","PDB_CHEM_ID":"AZM","PUBCHEM_CID":"1986","SNOMEDCT_US":"33664007","IUPHAR_LIGAND_ID":"6792","SECONDARY_CAS_RN":"1424-27-7","MESH_DESCRIPTOR_UI":"D000086"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1953-","companyName":"Teva Branded Pharm","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"13.0 hours","clearance":"0.65 mL/min/kg","bioavailability":"99%","fractionUnbound":"0.04%","volumeOfDistribution":"0.37 L/kg"},"publicationCount":8547,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"S01EC01","allCodes":["S01EC01"]},"biosimilarFilings":[],"originalDeveloper":"Teva Branded Pharm","recentPublications":[{"date":"2026 Mar 17","pmid":"41898586","title":"p-Aminobenzene-Sulfonamide Derivatives of Substituted Pyrimidines as Human Carbonic Anhydrase Inhibitors.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 27","pmid":"41896728","title":"Epidemiology, pharmacological treatment and invasive management of idiopathic intracranial hypertension in Austria: a nationwide, hospital-based, controlled analysis of insurance data.","journal":"The journal of headache and pain"},{"date":"2026 Jun","pmid":"41890785","title":"Using selective laser trabeculoplasty to manage glaucoma in a child with phakomatosis pigmentovascularis.","journal":"American journal of ophthalmology case reports"},{"date":"2026 Mar 23","pmid":"41890698","title":"Efficacy and Safety of Carbonic Anhydrase Inhibitors in the Management of Central Serous Chorioretinopathy.","journal":"Journal of vitreoretinal diseases"},{"date":"2026 Mar","pmid":"41884526","title":"Isotretinoin-induced Intracranial Hypertension Presenting as Unilateral Pulsatile Tinnitus.","journal":"Otology & neurotology open"}],"companionDiagnostics":[],"genericManufacturers":29,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Ajanta Pharma Ltd","Alembic","Alra","Ascot","Aurobindo Pharma Ltd","Breckenridge","Cadila","Chartwell Molecular","Epic Pharma Llc","Heritage Pharma","Hibrow Hlthcare","Indicus Pharma","Mankind Pharma","Micro Labs Ltd India","Mpp Pharma","Ne Rx Pharma","Novast Labs","Novitium Pharma","Rising","Rubicon Research","Somerset Theraps Llc","Strides Pharma","Sun Pharm Industries","Taro","Torrent","Vangard","Watson Labs","Zydus Lifesciences"],"status":"approved","companyName":"Teva Branded Pharm","companyId":"teva","modality":"Small molecule","firstApprovalDate":"1953","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-12-10T00:00:00.000Z","mah":"XGEN PHARMS","brand_name_local":null,"application_number":"ANDA040784"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-01-09T00:00:00.000Z","mah":"TARO","brand_name_local":null,"application_number":"ANDA040195"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-09-30T00:00:00.000Z","mah":"NOVAST LABS","brand_name_local":null,"application_number":"ANDA203434"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-01-16T00:00:00.000Z","mah":"CADILA","brand_name_local":null,"application_number":"ANDA205301"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-03-12T00:00:00.000Z","mah":"AJANTA PHARMA LTD","brand_name_local":null,"application_number":"ANDA211151"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":19,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T03:23:58.371945+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}